Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Surufatinib Maintenance in Advanced Biliary Tract Cancer
NCT06255262Phase 2Not yet recruiting
- Sponsor
- China Medical University
- Start
- Feb 2024
- Primary completion
- Oct 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in biliary tract cancer (BTC), sponsored by China Medical University. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06255262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255262.